← All trials
NCT01576419
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2010
- Primary completion
- Mar 1, 2011
- Completion date
- Sep 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 309
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- PMG Pharm Co., LtdLead sponsor
- Korea UniversityOverall official - principal investigator
- Inje UniversityOverall official - principal investigator
- Eulji UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Chungnam National UniversityOverall official - principal investigator
- Gachon UniversityOverall official - principal investigator
- Ajou UniversityOverall official - principal investigator
- Chonbuk National UniversityOverall official - principal investigator
- Hallym UniversityOverall official - principal investigator
- Chung-Ang UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.